Oliver Sartor MD
Director of the Radiopharmaceutical Trials, Chief of the Genitourinary Cancer Malignancy Group, Mayo Clinic, Rochester, MinnesotaDr. Oliver Sartor is a medical oncologist in the Division of Medical Oncology in the Department of Oncology at the Mayo Clinic in Rochester, Minnesota. He serves as Chair of the Genitourinary Cancer Disease Group and the Director of Radiopharmaceutical Clinical Trials for the Mayo Clinic Comprehensive Cancer Center.
Dr. Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 500 peer-reviewed articles, led or co-led multiple national and international clinical studies, including four phase III studies pivotal for FDA approval of drugs for advanced prostate cancer (Quadramet, Xofigo, Pluvicto, and Jevtana). He has lectured widely, and, at last count, has given invited lectures in 33 countries. He is the Medical Oncology Chair of the Genitourinary Cancer Committee of NRG, a national cancer research group.
Disclosures
- Consultant: Advanced Accelerator Applications (AAA); Astellas; AstraZeneca; Bayer; Blue Earth Diagnostics; Bavarian Nordic; Bristol Myers Squibb; Clarity Pharmaceuticals; Clovis; Constellation; Dendreon; EMD Serono; Fusion; Isotopen Technologien Muenchen; Janssen; Merck; Myovant; Myriad; Noria Therapeutics; Novartis; Noxopharm; Progenics; POINT Biopharma; Pfizer; Sanofi; Teneobio; Telix; Theragnostics
- Research funding: Advanced Accelerator Applications; Amgen; AstraZeneca; Bayer; Constellation; Endocyte; Invitae; Janssen; Lantheus; Merck; Progenics; Teneobio
Recent Contributions to PracticeUpdate:
- Low Testosterone in First Year of ADT Linked to Improved Outcomes
- Targeting the Androgen Receptor Confers In Vivo Cross-Resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-Resistant Prostate Cancer
- Survival With Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era"
- Leuprolide Plus Abiraterone More Effective in Prostate Cancer Than Abiraterone Alone
- PSA Helps Determine Whether to Treat or Watch After Radical Prostatectomy
- Clinical Relevance of AR-V7 in Castrate-Resistant Prostate Cancer
- AR-V7 Predicts Poor Response to Enzalutamide and Abiraterone in Prostate Cancer
- FDA Approves Radiotherapy for Metastatic Prostate Cancer